Literatur
Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009464.pub2
Escobar Y, Cajaraville G, Virizuela JA et al (2015) Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer 23(9):2833–2840
Haiderali A, Menditto L, Good M et al (2011) Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer 19(6):843–851
Schwartzberg L, Morrow G, Balu S et al (2011) Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5‑HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. Curr Med Res Opin 27(8):1613–1622
Roila F, Herrstedt J, Gralla RJ, Tonato M (2011) Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: guideline update and results of the Perugia consensus conference. Support Care Cancer 19(Suppl 1):S63–S65
Beusterien K, Grinspan J, Kuchuk I et al (2014) Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist 19(2):127–134
Andrews PLR (1992) Physiology of nausea and vomitting. Br J Anaesth 69:2S–19S
Davis MP, Walsh D (2000) Treatment of nausea and vomitting in advanced cancer. Support Care Cancer 8(6):444–452
Freistühler M (2009) Gastrointestinale Symptome. In: Kloke M et al (Hrsg) Grundwissen Palliativmedizin. DÄV, Köln
Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202
Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198
Roila F, Herrstedt J, Aapro M et al (2011) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243
NCCN Clinical Practice Guidelines in Oncology (2016) Antiemesis (NCCN Guidelines®)
Dronabinol. Arzneimittel-Fachinformation. https://panakeia.ch/
Tramer MR, Carroll D, Campbell FA, Reynolds DJ et al (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323(7303):16–21
Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2017) Leitlinienprogramm Onkologie: Supportive Therapie bei onkologischen PatientInnen – Langversion 1.1
Danksagung
UroEvidence dankt Claudia Bollig (Cochrane Deutschland) und Janine Weiberg (DGU) für die Durchsicht und Kommentare zu dieser Übersetzung.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
D.L. Dräger gibt an, dass kein Interessenkonflikt besteht.
Additional information
Die Zusammenfassung ist eine Übersetzung des Abstracts der Originalpublikation
Rights and permissions
About this article
Cite this article
Dräger, D.L. Einsatz von Cannabinoiden bei chemotherapieinduzierter Übelkeit und Erbrechen. Urologe 57, 54–58 (2018). https://doi.org/10.1007/s00120-017-0560-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-017-0560-8